Pharmacological management of dermatomyositis

Zoltán Griger, Melinda Nagy-Vincze, K. Dankó

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Dermatomyositis is a rare heterogeneous systemic autoimmune disease with multiple organ involvement which can result in significant disability and mortality. Despite the lack of placebo-controlled trials, glucocorticoids are considered to be the mainstay of initial management. Treatment strategies are mainly based on uncontrolled studies, evidence based guidelines for treatments do not exist. Areas covered: This review provides an overview of the currently available pharmacological treatments in the field of dermatomyositis including conventional immunosuppressants, biologics and topical agents. The role of antibodies in different treatment responses of dermatomyositis related clinicoserological syndromes is also discussed. A PubMed search was performed in order to find relevant literature for this review. Expert commentary: Early recognition and intervention is essential to ameliorate disease outcome. Determination of antibodies provide a useful key in diagnosis, clinical manifestations, malignancy, prognosis, and treatment response and may lead to wider acceptance of personalized medicine. Corticosteroids with adjunctive steroid-sparing immunosuppressive therapies are recommended to treat disease activity, prevent mortality, and reduce long-term disability. Combinations of second-line therapies or newer third-line therapies are used in severe, refractory, or corticosteroid-dependent diseases. Further research is required to assess the role of new therapies.

Original languageEnglish
Pages (from-to)1109-1118
Number of pages10
JournalExpert Review of Clinical Pharmacology
Volume10
Issue number10
DOIs
Publication statusPublished - Oct 3 2017

Fingerprint

Dermatomyositis
Pharmacology
Therapeutics
Immunosuppressive Agents
Adrenal Cortex Hormones
Precision Medicine
Mortality
Antibodies
Biological Factors
PubMed
Glucocorticoids
Autoimmune Diseases
Steroids
Placebos
Guidelines

Keywords

  • anti-MDA5
  • anti-Mi2
  • anti-TIF1
  • Antibodies
  • antisynthetase syndrome
  • azathioprine
  • cyclophosphamide
  • cyclosporine-A
  • dermatomyositis
  • intravenous immunoglobuline
  • methotrexate
  • mycophenolate mofetyl
  • rituximab
  • tacrolimus

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Pharmacological management of dermatomyositis. / Griger, Zoltán; Nagy-Vincze, Melinda; Dankó, K.

In: Expert Review of Clinical Pharmacology, Vol. 10, No. 10, 03.10.2017, p. 1109-1118.

Research output: Contribution to journalReview article

Griger, Zoltán ; Nagy-Vincze, Melinda ; Dankó, K. / Pharmacological management of dermatomyositis. In: Expert Review of Clinical Pharmacology. 2017 ; Vol. 10, No. 10. pp. 1109-1118.
@article{c38c3954f03b4545b96b36392d992b93,
title = "Pharmacological management of dermatomyositis",
abstract = "Introduction: Dermatomyositis is a rare heterogeneous systemic autoimmune disease with multiple organ involvement which can result in significant disability and mortality. Despite the lack of placebo-controlled trials, glucocorticoids are considered to be the mainstay of initial management. Treatment strategies are mainly based on uncontrolled studies, evidence based guidelines for treatments do not exist. Areas covered: This review provides an overview of the currently available pharmacological treatments in the field of dermatomyositis including conventional immunosuppressants, biologics and topical agents. The role of antibodies in different treatment responses of dermatomyositis related clinicoserological syndromes is also discussed. A PubMed search was performed in order to find relevant literature for this review. Expert commentary: Early recognition and intervention is essential to ameliorate disease outcome. Determination of antibodies provide a useful key in diagnosis, clinical manifestations, malignancy, prognosis, and treatment response and may lead to wider acceptance of personalized medicine. Corticosteroids with adjunctive steroid-sparing immunosuppressive therapies are recommended to treat disease activity, prevent mortality, and reduce long-term disability. Combinations of second-line therapies or newer third-line therapies are used in severe, refractory, or corticosteroid-dependent diseases. Further research is required to assess the role of new therapies.",
keywords = "anti-MDA5, anti-Mi2, anti-TIF1, Antibodies, antisynthetase syndrome, azathioprine, cyclophosphamide, cyclosporine-A, dermatomyositis, intravenous immunoglobuline, methotrexate, mycophenolate mofetyl, rituximab, tacrolimus",
author = "Zolt{\'a}n Griger and Melinda Nagy-Vincze and K. Dank{\'o}",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/17512433.2017.1353910",
language = "English",
volume = "10",
pages = "1109--1118",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Pharmacological management of dermatomyositis

AU - Griger, Zoltán

AU - Nagy-Vincze, Melinda

AU - Dankó, K.

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Dermatomyositis is a rare heterogeneous systemic autoimmune disease with multiple organ involvement which can result in significant disability and mortality. Despite the lack of placebo-controlled trials, glucocorticoids are considered to be the mainstay of initial management. Treatment strategies are mainly based on uncontrolled studies, evidence based guidelines for treatments do not exist. Areas covered: This review provides an overview of the currently available pharmacological treatments in the field of dermatomyositis including conventional immunosuppressants, biologics and topical agents. The role of antibodies in different treatment responses of dermatomyositis related clinicoserological syndromes is also discussed. A PubMed search was performed in order to find relevant literature for this review. Expert commentary: Early recognition and intervention is essential to ameliorate disease outcome. Determination of antibodies provide a useful key in diagnosis, clinical manifestations, malignancy, prognosis, and treatment response and may lead to wider acceptance of personalized medicine. Corticosteroids with adjunctive steroid-sparing immunosuppressive therapies are recommended to treat disease activity, prevent mortality, and reduce long-term disability. Combinations of second-line therapies or newer third-line therapies are used in severe, refractory, or corticosteroid-dependent diseases. Further research is required to assess the role of new therapies.

AB - Introduction: Dermatomyositis is a rare heterogeneous systemic autoimmune disease with multiple organ involvement which can result in significant disability and mortality. Despite the lack of placebo-controlled trials, glucocorticoids are considered to be the mainstay of initial management. Treatment strategies are mainly based on uncontrolled studies, evidence based guidelines for treatments do not exist. Areas covered: This review provides an overview of the currently available pharmacological treatments in the field of dermatomyositis including conventional immunosuppressants, biologics and topical agents. The role of antibodies in different treatment responses of dermatomyositis related clinicoserological syndromes is also discussed. A PubMed search was performed in order to find relevant literature for this review. Expert commentary: Early recognition and intervention is essential to ameliorate disease outcome. Determination of antibodies provide a useful key in diagnosis, clinical manifestations, malignancy, prognosis, and treatment response and may lead to wider acceptance of personalized medicine. Corticosteroids with adjunctive steroid-sparing immunosuppressive therapies are recommended to treat disease activity, prevent mortality, and reduce long-term disability. Combinations of second-line therapies or newer third-line therapies are used in severe, refractory, or corticosteroid-dependent diseases. Further research is required to assess the role of new therapies.

KW - anti-MDA5

KW - anti-Mi2

KW - anti-TIF1

KW - Antibodies

KW - antisynthetase syndrome

KW - azathioprine

KW - cyclophosphamide

KW - cyclosporine-A

KW - dermatomyositis

KW - intravenous immunoglobuline

KW - methotrexate

KW - mycophenolate mofetyl

KW - rituximab

KW - tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85030212343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030212343&partnerID=8YFLogxK

U2 - 10.1080/17512433.2017.1353910

DO - 10.1080/17512433.2017.1353910

M3 - Review article

C2 - 28691537

AN - SCOPUS:85030212343

VL - 10

SP - 1109

EP - 1118

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 10

ER -